Betty Yu, ScD

Betty Yu is the Director of acronymlab, a skin technology incubator. She received her formal training in the labs of Professors Daniel Blankschtein and Robert Langer at the Massachusetts Institute of Technology, where she earned a Doctor of Science in Chemical Engineering for her work elucidating the mechanisms of transdermal drug delivery.
After advancing a drug delivery platform to a first in human clinical study within Johnson & Johnson Pharmaceutical Research & Development, she returned to Cambridge as the first hire for Living Proof, a start-up acquired by Unilever PLC. At Living Proof, she led the intellectual property development and commercialization of a first in class skin material technology, NeotensilTM. Subsequently, the patent assignee was acquired by Shiseido Company LTD. 
Betty has also held advisory roles for Inkbox Ink (acquired by Société Bic S.A.) and Mindera Health.


John Doux, MD

John Doux currently serves as a board director of Lutris Pharma, and served previously as board chair of ValenzaBio (acquired by ACELYRIN), and as a board director of Ceptaris Therapeutics (acquired by Actelion Pharmaceuticals) and Palvella Therapeutics. A board certified dermatologist, Dr. Doux is a fellow of the American Academy of Dermatology. He earned his B.S. and M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow in the laboratory of Dr. David Woodley. He completed his training at Brigham and Women’s Hospital and Stanford Medical Center and earned an M.B.A. at the Wharton School of Business, where he was a Palmer Scholar.